Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Not sure if anybody has put this out there yet. Just a potential thought, and I may very well be wrong, but Bishop posted that last tweet about the contracts being signed from Grapevine, Texas. Grapevine is a suburb of Dallas, Texas. The Mavericks are the NBA team from Dallas and have already publicly supported the new NBA 2k eSport league, agreeing to field a team in this league. Mark Cuban is the owner of the Dallas Mavericks and has already personally advocated for and shown interest in eSports. Our CEO, Mr. Bishop has been linked with the Cubans, more specifically Mark's brother Jeff after appearing together in a Facebook live video and some Twitter interactions....... hmm.... could be interesting.
The alternative here is that Bishop's connecting flight from Florida to California stopped at one of the largest airports in the country in DFW. Being so large and serving such a large population, the Dallas/Fort Worth International Airport is not located in Dallas, however located closer to a suburb in the area called.... you guessed it, Grapevine. Flown in and out of that airport hundreds of times to go all over the country as I lived in Dallas for 20 years.
We will see what the PR holds tomorrow. Either way, good news coming, and I am looking forward to a nice move tomorrow.
Please continue to give me your cheap shares. Patience will win yet again
I hold shares here, but honestly I hate looking at this one. Least favorite stock I own. So much potential it's crazy. I do believe in what could happen here. Loads in the works.
REGARDING THE PR: As this was all announced yesterday via Twitter, I'm worried yesterday's gain was the result of today's pr. Great to see official pr, but same exact stuff from twitter. Hopefully I'm wrong here because the way this thing is trading, we are getting ready for a very interesting run IMO. Potentially the catalyst it needed. Probably see .002 test today
Patience will pay off here
It was never promised, but with the transparency and mannerisms of this CEO, I wouldn't be surprised if we see news before eod, or at least a tweet or Facebook live. If nothing today, then we keep loading at these sub penny levels and get ready to take off soon!
Mr. Bishop very much known for delivering news towards EOD. Wouldn't doubt we see it in the last 30 minutes of the trading day to give us that nice .01+ close.
Wait for it... ;)
For the new people here.... Hold strong. This is the usual movement for this one. We will be over a penny shortly, so load up while you can!
Smooth sailing here. Adding early today.
Still like what we have going on here with $USRM. Financials looking solid moving forward. Would love to see news this week about RMAT approval, or even an update about the MARVEL trials, however without news... I anticipate the market pulling back a little bit here. May linger and churn right around the mid-low 8's range, slowly heading south until we hear something solid from the company or the FDA.
Predicted movement for the day IMO: would not be surprised to see a quick spike green after open bringing us up a few ticks, followed by an emotional AM pull back (where I will be adding if it happens), some nice churning in the upper 8s / low 9s, and then a breakout to .01+ where we should close IMO. Obviously some major news would change this, and with all we have in the works here, major news would not surprise me in the slightest today.
Really consolidating well. Company is doing everything right, and the chart looks really good IMO. Could see nice red to green at the end here
Too much going for this company for this to stay sub-penny for much longer. I highly doubt this comes back below a penny again once it breaks through the next time. This is a rare situation. Good things in the works here. Churning nicely today, I like what I see. Will close the week well into the .01s IMO. LONG HOLD.
Great to see green today here. Revolutionary stuff perhaps in the works
Loads of good stuff in the works here. Executive order from President COULD be huge. Realistically, could be nothing also. As is often the case, we wait and see.
If you actually do your DD, you will understand that this is not your usual OTC penny stock. This is one of those rare, long term holds in this area of the market. People that are encouraging sales or claim to be shorting this stock are simply just trying to drive the market down to find a lower entry point or to average down. Unfortunate for them, because if they shorted, they are going to lose lots of money...
Hold them.
All part of the anticipated emotional dip we talked about all weekend long... everything moving EXACTLY how investors SHOULD want.
Should see the penny break today
Honestly, I think we do see pennyland this week with AMLH. I think we will go up a few ticks to start the day tomorrow, but after that I anticipate the emotional dip. I am going to do my best tomorrow morning to load a bit more on the dip, if it occurs. If not, then it soars and my new biggest problem is that I didn't buy more a week ago! Great stuff going on here. Looking forward to a fun ride.
Not trying to come on here to boost this stock, but even if this stock goes down, I am adding where I can because I actually believe in Mr. Bishop and the potential of this industry. If you don't understand the rise of eSports and the gaming industry, do some research and you will understand why $AMLH is ready to take off and why this is a company to really invest in. The CEO is working tirelessly to make AMLH successful. Only a matter of time....
Added today. Big things coming from this company. I have never seen a CEO that works as hard as this man does for this company. This industry is just setting up as well, and Mr. Bishop is positioning us well. Incredible strength showed by $AMLH today to come out of that not too surprising dip and close green. Wow. There are few OTC stocks I truly believe in, but this is one of them.
Really seems that $VDRM has set the bottom. Somewhat fair IMO to say that we are waiting to hear update from FDA. Don't expect too much real solid movement until then
What every USRM investor needs to know!! Below is why U.S. Stem Cell Inc. is going to skyrocket. I know I may sound like the crazy man connecting the dots here, but if you bear with me and read my piece, I promise that you will understand why USRM is such a crazy prospect. Let’s begin with some background to lay the foundation for the puzzle, or to catch anybody that is new here up to speed.
USRM is a Florida corporation and leader in novel regenerative medicine solutions and physician-based stem cell therapies to human and animal patients.
The company focuses on discovering/developing cell based therapy options to treat/cure diseases by repairing/replacing damaged tissues, cells, and organs. The drug being reviewed heavily by the FDA right now and in the clinical trial stage is called MyoCell, a muscle stem therapy that restores the capabilities of the heart of someone with heart damage caused by a heart attack and allows this person to begin to return to normal cardiac strength. The procedure is a minimally invasive operation in which a small amount of tissue is taken from the thigh. The cells from the thigh muscle are then isolated and cultured using U.S. Stem Cell's proprietary cell-culturing process. Then, the muscle cells are delivered to the affected regions in the heart where the cells begin to populate the areas of scar tissue.
So, knowing this, the drug has recently received reactivation status with the FDA. The trials became inactive because patients were not actively being enrolled. During the MARVEL phase 1 trial, the results were quite positive. They showed that patients using the treatment were able to increase their walking distance by a significant amount throughout the 6-minute duration of the test when compared to other patients using a placebo.
So, why is the reactivation status received on April 10th, 2017 so important? Well, this is because USRM has applied to the FDA for Regenerative Medicine Advanced Therapy (RMAT) designation for MyoCell as part of the MARVEL trials. So, according to the FDA, in order to receive RMAT designation, the request must be accompanied by an Investigational New Drug application, and that drug must be in the active stage of its trials. So, when the FDA moved to reactivate the trials, the door then opened for USRM to seek RMAT designation for MyoCell. RMAT designation is granted for a regenerative medicine therapy that is intended to treat, modify, reverse, or cure a serious or life-threatening disease and demonstrates preliminary clinical evidence that the product has the potential to address unmet medical needs for a disease. U.S. Stem Cell feels as if MyoCell meets these qualities, and personally, I agree.
If the RMAT designation is granted, then the approval process for MyoCell would likely be expedited. If my research is correct, then we should have a response from the FDA regarding the RMAT designation by June 10. This is later than I originally projected, and I am aware that this is different from what many others have projected as well. U.S. Stem Cell put out the PR announcing the reactivation on April 10, 2017, so I presume that this is also when the 60-day clock resets for the RMAT designation approval. I may be slightly off on this, and the clock may have reset on March 30, putting the deadline at May 30, or the date could be anywhere in that range. Unfortunately, the clock resets whenever the FDA requests additional information, which is what happened to USRM when they originally applied for the RMAT designation on January 27, 2017 as part of the MARVEL trial. Either way, I would expect to hear about the RMAT designation by late May. The Office of Tissues & Advanced Therapies (OTAT) at the FDA states that they will respond within 60 days of receiving an RMAT designation request. I am not just pulling that out of nowhere.
OKAY… so this is basically all the common knowledge that is out there so far. Next is where we begin to connect the dots and understand why things should come together nicely for USRM.
The man appointed by President Donald J. Trump to head the FDA is named Scott Gottlieb. On the docket for the U.S. Senate Health, Education, Labor, and Pensions Committee on Wednesday, April 26, 2017 at 10AM is “to consider… (among other things)… the nomination of Scott Gottlieb, of Connecticut, to be Commissioner of Food and Drugs, Department of Health and Human Services.” This is massive for the stakeholders in USRM. As soon as Mr. Gottlieb is in, the stance of the FDA regarding stem cells could change drastically, playing in favor of USRM.
The FDA has traditionally had a rather difficult stance when it comes to stem cells, but Mr. Gattlieb wrote an article in 2012 for the WSJ supporting the use of cell-based therapies. He even worked with companies developing such therapies in the past. He has said less is more when speaking with regards to the FDA’s regulation of stem cells. He wants to work in coordination of the new President’s agenda of “slashing restraints” the FDA has put in place. This sounds pretty solid for U.S. Stem Cell, Inc.
Mr. Gottlieb is in favor of the “right-to-try” movement. This allows patients with terminal illnesses to use investigational drugs or treatments. Over half of state legislatures have passed, or plan to pass, such legislation. Those that have passed have had minimal opposition. One state that has passed such legislation is the state of Indiana, with the bill being signed by the current sitting Vice President, Mike Pence. Mr. Gottlieb and President Trump have expressed both support and interest in working with Congress to pass a national “right-to-try” bill. While this does not necessarily line up directly with MyoCell, the technology it brings and the doors it could open for not just USRM, but the entire stem cell industry is fantastic.
The likely next Commissioner of the FDA is a cancer survivor himself, having successfully beaten Hodgkin’s lymphoma. So, it is no surprise that he is in favor of giving terminally ill patients access to drugs that are still in clinical trials to potentially save their own life, and quite possibly millions of other lives down the line.
This could mean crazy jumps for USRM in the near future! Okay, now lets wrap things up.
Financially, the books are starting to look pretty solid for this company as well. Revenues are up 40% from $2,200,000 in 2015 to $3,080,000 in 2016. Total assets are almost doubled, up 86% from $229,000 in 2015 to $427,000 in 2016. Large increases in assets can be scary in larger companies because it can represent stagnation of sales and inventory sitting in your warehouse. If you are new to the OTC, increasing assets is often a good thing because it shows the legitimacy and the expansion of the company when it is paired with increasing revenues like we are here. One of the most encouraging facts to be taken from the financial reports is that this is the first time in the company’s history that they ended the year on a cash positive note, being an impressive $112,000 cash positive to end 2016 compared to being $844,000 cash negative in 2015.
USRM is also beginning to get involved overseas. They reached an agreement with Kuwait-based High Rising Group for the development and launch of U.S. Stem Cell Middle East. The first overseas clinic in Kuwait City is set to open and be operational by the end of 2017. Qatar and Dubai are not far behind, with other locations like Bahrain, United Arab Emirates, Saudi Arabia, Jordan, and Egypt also in the works.
U.S. Stem Cell, Inc. also announced via 8-K that it has entered into an agreement with General American Capital Partners (GACP) in which GACP will invest $2,500,000 to open 10 new clinics in the United States called “Stem Cell Centers of Excellence.” Part of the deal is that USRM sold $500,000 of “equipment” to GACP, but then leased the “equipment” back for basically $500,000. The “equipment” mentioned is the tissue banking facility, which will be leased for 3 years.
Given all of the above information, I would say that USRM is just waiting to explode. We finally had a nice green day today on what is the notoriously horrific day of the week in Tuesday. Once Mr. Gottlieb is given the reins of the FDA, I anticipate a somewhat rapid approval for the RMAT designation and for the eventual approval of MyoCell and other USRM cell-based therapies. The company has solid/improving financials, and I fully expect that the CEO, Mr. Mike Tomás, will propel this company forward. For those reading, hopefully this means financial prosperity. For the United States of America and the entire world, hopefully this can mean lives saved and making the world a better place.
We closed down today, but strong by $USRM not to dip below 7. May be inevitable, but was nice to see today at least. One day at a time in this business lol. As I have said, waiting for the FDA approval here which is expected WITHIN 60 days of March 30th, is the key to this one running to potentially $$$ levels and opening the door for acquisitions. Long term hold on this one, looking to buy the dips.
Scary to say on the OTC, but I believe in $AMLH and it's CEO, Christian Bishop. Nice gains today following Bishop's Facebook video. Lots of exciting news in the video. Everything in the company's power has been done to remove SS, now we just wait. Brought in PR firm to work towards getting solid pr in places like WSJ. Looking for big wins, not just quick penny upticks. Looking to set up meetings with groups like Snapchat, Facebook, and YouTube. Bringing on investor groups that will NOT dilute stock. I will be buying the dips on this one. If you are willing to be patient, $AMLH will have an awesome return.
Ask getting really thin. Break out coming. Loading these low 6's while I can!
This is a long and strong hold. Saw some decent support today. Hesitant to do so, but may add more tomorrow on the inevitable dip. This one is really contingent on the FDA approval that we are expecting within 60 days of March 30th. Hopeful here because I like what the company is doing. We will see. Honestly, will probably move red again tomorrow. HOLD AND POTENTIAL ADDS HERE!
Today, $VDRM was running on news for the parts of the day it was green. I added a bit before the pr and then was hopeful that would give it even more of a run. The issue here is that the pr is meant to cover up this lawsuit. Regardless of your opinions on the suit, the pr is simply meant to be a distraction I believe. While I think we continue this downward trend of running red until FDA news is released, I do stand by my previous statement that if somebody is willing to file a suit against Otiko and the company, then that means their product is solid. If it was a bad product, I doubt anybody would go to such effort to get something out of it. Holding this one long term because we are still a ways out (roughly 7-8 weeks I believe) from the FDA approval that could really get this thing moving.
Buying pressure. Expecting a green close today. After today, wouldn't be shocked by a few red days. I am looking to add significantly leading up to FDA approval. Long term hold. Patience will pay off here.
I think the annual report looks solid for $VDRM. The financials look good, and my thought process is that if people are wanting to file a lawsuit, that means what the company is doing is serious. If they were pushing some terrible product, then I don't think anybody would file a lawsuit. I'm optimistic about it (which may be a bad idea in this market lol). Personally if there is a dip, I will buy because this stock is a long hold for me. Patience will pay off here.
This can close green today in mid 9s. Showing great strength to bounce from 6's back up to 8's. Should see a dime again soon.
Volume looking nice to begin upward movement. Should see 2's to close out the day
Long term play here for sure. Slow and steady. Still a few weeks out from the company's projected FDA approval on the new drug. If all goes well this could easily hit the dollar mark.
Really liking $USRM long term